| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Mar, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -62,210 | -37,300 | -28,930 | 0 | 0 |
| Net Income Growth | -66.78% | -28.93% | unch | unch | unch |
Metacrine Inc (MTCR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.5814 -0.0076 (-1.29%) 06/20/23 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.5814 unch (unch) -
for Tue, Jun 20th, 2023
Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The company's program includes MET409 and MET642 which are in clinical trial. Metacrine Inc. is based in San Diego, United States.
Fiscal Year End Date: 12/31